• 25 June 2018

    The challenges of using stem cells in neurology

    The development of stem-cell based therapies has been slow even though there are many theoretical applications and benefits associated with these therapies. The challenges of translating potential drugs from clinical...

  • 20 June 2018

    Another BACE inhibitor fails in phase III trials

    On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the...

  • 22 May 2018

    PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...

Go Top